Delving into the Latest Updates on Sodium Thiosulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Monosulfanemonosulfonic acid, Sodium Aurotiosulfate, Sodium thiosulfate (USP)

+ [12]

Target-

Mechanism

Sulfur atom donors

Therapeutic Areas

Otorhinolaryngologic DiseasesOther DiseasesNeoplasms+ [1]

Active Indication

OtotoxicityDisinfectantsCyanide poisoning+ [3]

Inactive Indication

Calciphylaxis

Originator Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Active Organization

Decibel Therapeutics, Inc.

Fennec Pharmaceuticals, Inc.

Norgine BV

+ [5]

Inactive Organization

U.S. Army War College

Drug Highest PhaseApproved

First Approval Date

JP (11 May 1984),

Poisoning

RegulationFast Track (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (US), Orphan Drug (US)

Login to view timeline

Structure

Molecular FormulaH12Na2O8S2

InChIKeyJIWXHKJJHDWKGC-UHFFFAOYSA-N

CAS Registry10102-17-7

The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.

Start Date01 Dec 2024

Sponsor / Collaborator

University of Pittsburgh

[+1]

CTIS2023-510255-34-00 / Not yet recruitingIIT

A prospective, multi-centre, open-label, investigator-initiated randomised controlled study investigating calcinosis cutis in patients with systemic sclerosis undergoing treatment with sodium thiosulfate assessed by novel biomarkers and diagnostic imaging

Start Date22 May 2024

Sponsor / Collaborator

Århus Universitetshospital

TCTR20240520004 / Not yet recruitingPhase 3IIT

Efficacy of intratympanic sodium thiosulfate gel injection to preventisplatin-induced ototoxicity: a randomized controlled trial

Start Date20 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Sodium Thiosulfate

Login to view more data

100 Translational Medicine associated with Sodium Thiosulfate

Login to view more data

100 Patents (Medical) associated with Sodium Thiosulfate

Login to view more data

1,306

Literatures (Medical) associated with Sodium Thiosulfate

01 Dec 2024·CLINICAL NEPHROLOGY

Microarray analysis of microRNA profiles for assessing the therapeutic effects of sodium thiosulfate on end-stage renal disease combined with coronary artery calcification

Article

Author: Zhan, Yuanying ; Long, Jing ; Zheng, Yinglai ; Wang, Hua ; Zheng, Youfeng ; Liang, Ji

BACKGROUND:

Coronary artery calcification (CAC) is a common complication in patients with end-stage renal disease (ESRD), which causes of increased cardiovascular mortality in maintenance hemodialysis patients. This study examined how sodium thiosulfate (STS) treatment affects the microRNA (miRNA) expression profiles of ESRD patients combined with CAC.

MATERIALS AND METHODS:

A total of 18 patients with ESRD complicated with CAC were assigned to a control group that received conservative treatment or a test group that received STS treatment. The 2 groups were then sub-divided into a CGBT group (control group before treatment), TGBT group (test group before treatment), CGAT group (control group after treatment), and TGAT group (test group after treatment). Samples of peripheral venous blood were collected for analysis of biochemical indexes (hs-CRP, ALB, CHO, TG, Ca, P, BUN, Cr, bALP, iPTH, and FGF23) and used to screen for differentially expressed miRNAs that were displayed by hierarchical clustering and in a volcano plot. The functional roles of miRNA target genes were analyzed by Gene Ontology and Kyoto Encycolopedia of Genes and Genomes pathway analyses. Several miRNAs in serum samples were identified using quantitative real time PCR.

RESULTS:

STS treatment did not significantly change the biochemical indexes. A microarray analysis identified 67 miRNAs that were differentially expressed in the TGAT group vs. the TGBT group, and 28 -miRNAs that were differentially expressed in the CGAT group vs. the CGBT group. The miRNA target genes were associated with signal transduction, transcriptional regulation, cytoplasm and protein binding processes, the MAPK signaling pathway, PI3K-Akt signaling pathway, and various pathways in cancer. Validation experiments confirmed the suppressive effect of STS treatment on miR-337-5p/miR-409-5p expression and the promotive effect of STS on miR-376a-3p expression.

CONCLUSION:

MiR-337-5p/miR-409-5p/miR-376a-3p might be key regulators involved with the therapeutic effects of STS treatment in ESRD patients associated with arterial calcification.

01 Dec 2024·EJSO

Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review

Review

Author: Solanki, Sohan Lal ; Kuberkar, Deepali V ; Kuberkar, Deepali V. ; Bhatt, Aditi ; Ambulkar, Reshma ; Salunke, Bindiya ; Gangakhedkar, Gauri

The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.

01 Dec 2024·MARINE POLLUTION BULLETIN

Detoxification effect of sodium thiosulfate on cadmium poisoning in Litopenaeus vannamei and the mechanisms of intestinal flora regulation

Article

Author: Wang, Xuejie ; Yu, Jianbo ; Dong, Jiaxin ; Gao, Shan ; Hou, Danqing ; Sun, Chengbo ; Li, Ting

Cadmium (Cd) is currently one of the heavy metals with the highest environmental toxicity impact. Sodium thiosulfate (Na₂S₂O₃) is a commonly used heavy metal detoxification drug in clinical practice, however, it has not been used for Cd detoxification of Litopenaeus vannamei. The present study used exposure of L. vannamei to 150 μg/L of Cd while mitigating in the addition of 75 μg/L of Na₂S₂O₃ for 28 days. The goal was to study the detoxifying effect of Na₂S₂O₃ on L. vannamei poisoning and its role in intestinal flora. The results showed that the growth of Cd group was inhibited, and the growth rate and weight gain of Cd + ST group were greater than that of Cd group. The function and structure of L. vannamei intestinal microorganisms were significantly changed under Cd stress. This work reveals that Na₂S₂O₃ can mitigate the damage caused by this concentration to L. vannamei to a certain extent.

67

News (Medical) associated with Sodium Thiosulfate

13 Nov 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Orphan DrugDrug Approval

31 Oct 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate and Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Drug ApprovalFinancial StatementOrphan Drug

05 Sep 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ETLocation: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor Event: Cantor Fitzgerald Global Healthcare ConferenceDate: September 19, 2024Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ETLocation: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1 For additional information, please visit the investor relations section of the Company’s website at:https://investors.fennecpharma.com/events-and-presentations/events. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Drug ApprovalOrphan Drug

100 Deals associated with Sodium Thiosulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01091	Sodium Thiosulfate	V03AB06	DB09499

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ototoxicity	US	Fennec Pharmaceuticals, Inc.	20 Sep 2022
Disinfectants	JP	Kenei Pharmaceutical Co Ltd.	12 Nov 2013
Cyanide poisoning	AU	Pfizer Australia Pty Ltd.	30 Aug 2007
Poisoning	JP	Nichi-Iko Pharmaceutical Co., Ltd.	11 May 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Calciphylaxis	Phase 3	US	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Phase 3	CA	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Phase 3	GB	Hope Pharmaceuticals, Inc.	24 May 2017
Neoplasms	Phase 1	US	Decibel Therapeutics, Inc.	21 Feb 2020
Neoplasms	Phase 1	AU	Decibel Therapeutics, Inc.	21 Feb 2020
Hearing Loss	Preclinical	US	Fennec Pharmaceuticals, Inc.	31 Jan 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04541355 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Ototoxicity \| Nasopharyngeal Carcinoma ... View more	16	Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+Cisplatin	zekpinkfyb(jxgquvnqlp) = lrdyoayvhy vpsyerfqbm (zrxkcopqig, yfqtnffind - akmhctbakk) View more	-	28 Jun 2024
ISN WCN2024	Not Applicable	Calciphylaxis	-	Sodium Thiosulphate	uuwyatxjhy(nndfhesjxx) = kgtpoyuqqt oxbbifpbjd (jmjmnnhazc )	-	01 Apr 2024
NCT03267277 (CTgov)	Phase 2/3	Idiopathic Inflammatory Myopathies \| Dermatomyositis \| Calcinosis	15	Sodium Thiosulfate	bcugvuzbvc(zqveldqemi) = ycoenmbutq odmczcdzaj (ntgnndmwbz, irxipqncba - krfdqakseo) View more	-	26 Feb 2024
WCD2023	Not Applicable	Calciphylaxis Adjuvant	-	Intralesional sodium thiosulfate	moxtwpgxsj(bfnrbhslmm) = ntoiqguiui zsnztejhso (spvirhmszb ) View more	-	07 Jul 2023
EMA Manual	Not Applicable	Ototoxicity	104	cisplatin (with different types of cancer)	dodmczjuty(ysmichymbp) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. rvrlmewzsp (kqunhesmvk ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with different types of cancer)
EMA Manual	Not Applicable	Ototoxicity	109	cisplatin (with hepatoblastoma)	upbpzxclle(uqkethubue) = yhnfslmttc rnxkqpblkl (ftzrqaluwt ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with hepatoblastoma)	upbpzxclle(uqkethubue) = vjsygfotod rnxkqpblkl (ftzrqaluwt ) View more
NCT04262336 (ASCO2023) Manual	Phase 1	Ototoxicity	19	DB-020	chvgexvvyu(mrcdaqpxvl) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. nxmgppyctq (vszshgcpgf ) View more	Positive	26 May 2023
				Placebo
ASN2022	Not Applicable	Acidosis	-	Sodium Thiosulfate (STS)	dmcxbceuyc(xdcvuiacff) = the patient's severe pain persisted despite escalation of analgesic therapy prompting consideration of hospice zteyixzwsn (ziqurrgose )	-	06 Nov 2022
				Bicarbonate therapy
NCT04262336 (Corporate Publications) Manual	Phase 1	Hearing Loss	19	DB-020	xfsjjplgsa(gwiuzoxqud) = fnlildsdtr okzgniskfu (jdzdjvihgq )	Positive	28 Jun 2022
				Placebo	xfsjjplgsa(gwiuzoxqud) = cramlowogl okzgniskfu (jdzdjvihgq )
MO599 (ERA2022)	Not Applicable	Calciphylaxis Maintenance	-	Optimized Sodium Thiosulfate Therapy	lozxxtjkmu(gxzfotldzq) = most adverse events appeared in the course of increasing the STS dose and would be relieved when we stopped adding it or decreased to the day-before dose fqxhwplcuu (ccukptguqm )	Positive	03 May 2022